Govind Patel, MD
Internal Medicine · Fairmont, WVNPI 1861478109
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $56,108 of the $58,957 with a category attached, or 95.2%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 95.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2022 at $25,642 and has fallen 99.8% since, to $42 in 2025. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $310.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$56K
- AstraZeneca$406
- AbbVie$244
- Sunovion Pharmaceuticals Inc.$196
- Sanofi$185
- Mylan Specialty L.p.$175
- plus $2K from 25 others
What the payments were for
- Consulting fees$56,10895%
- Speaking & faculty fees$1850%
- Food & beverage$2,6304%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $56,108 |
| AstraZeneca | 27 | $406 |
| AbbVie(2 entities) | 15 | $244 |
| Sunovion Pharmaceuticals Inc. | 12 | $196 |
| Sanofi | 1 | $185 |
| Mylan Specialty L.p. | 9 | $175 |
| Avanir Pharmaceuticals, Inc. | 10 | $171 |
| Novo Nordisk | 9 | $157 |
| Lilly USA, LLC | 10 | $156 |
| Novartis | 9 | $137 |
| Amarin Pharma, Inc. | 9 | $122 |
| Boehringer Ingelheim | 7 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $104 |
| GSK | 5 | $86 |
| Scilex Pharmaceuticals Inc. | 5 | $73 |
| Lundbeck LLC | 3 | $62 |
| Johnson & Johnson | 3 | $59 |
| UCB, Inc. | 3 | $58 |
| Bayer | 3 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $48 |
| Almatica Pharma LLC | 2 | $42 |
| Neurelis, Inc. | 1 | $39 |
| Biogen | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Alkermes, Inc. | 1 | $18 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| SK Life Science, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$185
How this compares
$58,957 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $86,171 |
| JanuviaSitagliptin Phosphate | 58 | $46,951 |
| JardianceEmpagliflozin | 47 | $43,707 |
| RybelsusSemaglutide | 28 | $40,376 |
| OzempicSemaglutide | 19 | $38,149 |
| MounjaroTirzepatide | 23 | $23,371 |
| TrulicityDulaglutide | 15 | $19,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,305 |
| LinzessLinaclotide | 21 | $16,760 |
| TradjentaLinagliptin | 16 | $13,363 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 31 | $9,692 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,971 |
| Lidocaine | 18 | $7,535 |
| XareltoRivaroxaban | 23 | $7,455 |
| RestasisCyclosporine | 13 | $6,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $157 | $78,52547 claims |
| Boehringer IngelheimJardiance, Tradjenta | $118 | $57,07063 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $156 | $46,667130 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta | $86 | $35,96874 claims |
| AbbVieLinzess, Restasis, Creon, Lumigan | $244 | $33,72258 claims |
| AstraZenecaLokelma, Symbicort, Brilinta | $406 | $13,18147 claims |
| Johnson & JohnsonXarelto | $59 | $7,45523 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $6,56269 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $56,108 | $6,17613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Fairmont
- William ChapmanCharleston$1.7M
- David PickeringParkersburg$599K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
- Ali KhanBuckhannon$21K
- Joseph HashemBerkeley Springs$21K
- David PatickHuntington$18K
- Phillip TriplettCharleston$17K
- Atul ShettyWeirton$15K
- Roy BowdenCharleston$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.